Understanding how cell processes affect HER2-positive breast cancer
Intersection of autophagy and vesicle trafficking in Her2-positive breast cancer
['FUNDING_R01'] · UNIVERSITY OF CINCINNATI · NIH-11098576
This study is looking at how certain processes in cells work together in HER2-positive breast cancer, which affects about 1 in 4 breast cancer patients, to find new ways to stop the cancer from spreading and becoming resistant to treatment, with the hope of improving care for those living with this type of cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CINCINNATI (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-11098576 on ClinicalTrials.gov |
What this research studies
This research investigates the complex interactions between autophagy and vesicle trafficking in HER2-positive breast cancer, a subtype that affects about 25% of breast cancer patients. By utilizing mouse models, the study aims to uncover the molecular mechanisms behind metastasis and therapeutic resistance, which are significant challenges in treating this aggressive cancer. The researchers have previously found that blocking a specific autophagy gene can prevent tumor growth and spread by altering the behavior of the HER2 protein. This work could lead to new therapeutic strategies that improve outcomes for patients with HER2-positive breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with HER2-positive breast cancer.
Not a fit: Patients with other subtypes of breast cancer that do not express HER2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HER2-positive breast cancer, potentially reducing metastasis and improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting autophagy and vesicle trafficking in cancer treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
CINCINNATI, UNITED STATES
- UNIVERSITY OF CINCINNATI — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GUAN, JUN-LIN — UNIVERSITY OF CINCINNATI
- Study coordinator: GUAN, JUN-LIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.